GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Net Issuance of Preferred Stock

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Net Issuance of Preferred Stock : ₦0 Mil (TTM As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

GlaxoSmithKline Consumer Nigeria's net issuance of preferred for the three months ended in Jun. 2023 was ₦0 Mil. The number is 0, which means that GlaxoSmithKline Consumer Nigeria has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

GlaxoSmithKline Consumer Nigeria's net issuance of preferred for the trailing twelve months (TTM) ended in Jun. 2023 was ₦0 Mil.


GlaxoSmithKline Consumer Nigeria Net Issuance of Preferred Stock Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Net Issuance of Preferred Stock Chart

GlaxoSmithKline Consumer Nigeria Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlaxoSmithKline Consumer Nigeria Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GlaxoSmithKline Consumer Nigeria Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₦0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Consumer Nigeria Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA
GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines